Position in IBRX
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$43,906
New position
Shares Held
5,015
first reported quarter
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#319
of 400 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026HOLLENCREST CAPITAL MANAGEMENT holds $1,718,963 across 26 Biotechnology names. IBRX ranks #5 (2.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
11,374 | $927,094 | |
| 2 | LBRX |
Lb Pharmaceuticals Inc
|
13,722 | $445,347 | |
| 3 | CYTK |
Cytokinetics Inc
|
1,200 | $102,228 | |
| 4 | NKTR |
Nektar Therapeutics
|
760 | $53,055 | |
| 5 | IBRX |
ImmunityBio, Inc.
This page
|
5,015 | $43,906 | |
| 6 | ACAD |
Acadia Pharmaceuticals Inc
|
1,000 | $25,300 | |
| 7 | AXSM |
Axsome Therapeutics, Inc.
|
100 | $24,477 | |
| 8 | CRSP |
CRISPR Therapeutics AG
|
375 | $20,452 |
All Filings in IBRX
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $43,906 | 5,015 | Shares | Sole | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||